Cardiovascular prevention may be fundamentally misguided by focusing on cholesterol snapshots rather than lifetime accumulation. Current guidelines emphasize achieving specific LDL cholesterol targets at particular moments, yet mounting evidence suggests this approach overlooks the more critical factor: cumulative exposure over decades. The paradigm shift draws from epidemiological studies, genetic research on familial hypercholesterolemia, and Mendelian randomization analyses showing that cardiovascular damage accumulates based on total cholesterol burden throughout life, not just levels measured in middle age or later. This perspective challenges the conventional treatment model by proposing LDL cholesterol should be managed like other endocrine conditions where early intervention prevents long-term complications. Evidence from longitudinal cohort studies demonstrates that individuals with modestly elevated cholesterol starting in young adulthood face substantially higher cardiovascular risk than those achieving identical cholesterol levels only later in life through medication. The implications extend beyond current risk calculators, which predominantly weight recent measurements and short-term projections. For younger adults with extended life expectancy, this framework suggests earlier intervention could yield disproportionate benefits by preventing decades of arterial cholesterol accumulation. However, implementing this approach requires balancing potential medication side effects against uncertain future benefits, particularly in asymptomatic younger populations. The endocrine model offers a compelling theoretical foundation, though practical application demands careful consideration of individual risk-benefit profiles and long-term medication tolerance across different age groups.